Functionalized fullerenes represent a new class of photosensitizer (PS) that is being investigated for photodynamic therapy (PDT) of various diseases, including cancer. We tested the hypothesis that fullerenes could be used to mediate PDT of intraperitoneal (IP) carcinomatosis in a mouse model. In humans this form of cancer responds poorly to standard treatment and manifests as a thin covering of tumor nodules on intestines and on other abdominal organs. We used a colon adenocarcinoma cell line (CT26) stably expressing luciferase to allow monitoring of IP tumor burden in BALB/c mice by noninvasive real-time optical imaging using a sensitive low-light camera. IP injection of a preparation of N-methylpyrrolidinium-fullerene formulated in Cremophor-EL micelles, followed by white-light illumination delivered through the peritoneal wall (after creation of a skin flap), produced a statistically significant reduction in bioluminescence and a survival advantage in mice. From the Clinical Editor: This team of investigators report on functionalized fullerenes, to be used as photosensitizer for photodynamic therapy and demonstrate the efficacy of this method in an intraperitoneal carcinomatosis mouse model.
|Original language||English (US)|
|Number of pages||10|
|Journal||Nanomedicine: Nanotechnology, Biology, and Medicine|
|State||Published - Dec 2011|
Bibliographical noteFunding Information:
Conflict of Interest Statement: At the time of the research Tim Wharton was an employee of Lynntech Inc. Pawel Mroz, Tim Wharton and Michael R Hamblin are inventors on a patent describing the use of fullerenes as photosensitizers for PDT that has been licensed by Lynntech. The Hamblin laboratory has received funding in Phase 1 and 2 SBIR grants awarded to Lynntech.
- Disseminated abdominal cancer
- Functionalized fullerene
- Hydroxyl radicals
- Micellar formulation
- Photodynamic therapy